169 related articles for article (PubMed ID: 20651319)
1. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
Harrison DJ; Huang X; Globe D
Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
[TBL] [Abstract][Full Text] [Related]
2. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
5. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
6. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
8. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
10. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306
[TBL] [Abstract][Full Text] [Related]
11. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M
Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
13. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
Weycker D; Yu EB; Woolley JM; Oster G
Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns of anti-TNF agents in Italy: an observational study.
Punzi L; Matucci Cerinic M; Cantini F; Bagnato G; Fiocco U; Ferri C; Bombardieri S
Reumatismo; 2011 Mar; 63(1):18-28. PubMed ID: 21509346
[TBL] [Abstract][Full Text] [Related]
16. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.
Bullano MF; McNeeley BJ; Yu YF; Quimbo R; Burawski LP; Yu EB; Woolley JM
Manag Care Interface; 2006 Sep; 19(9):47-53. PubMed ID: 17017313
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of TNF antagonists in routine clinical practice and costs].
Prokes M
Vnitr Lek; 2009 Jan; 55(1):45-53. PubMed ID: 19227955
[TBL] [Abstract][Full Text] [Related]
18. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)].
Rubio-Terrés C; Ordovás Baines JP; Pla Poblador R; Martínez Nieto C; Sánchez Garre MJ; Rosado Souvirón MA; Sierra Muñoz A; Sánchez Mateo M;
Farm Hosp; 2007; 31(2):78-92. PubMed ID: 17590116
[TBL] [Abstract][Full Text] [Related]
19. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
Harley CR; Frytak JR; Tandon N
Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
[TBL] [Abstract][Full Text] [Related]
20. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.
Borah BJ; Huang X; Zarotsky V; Globe D
Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
